

## Freedom of Information Request - FOI2024/339

### Thank you for your Freedom of Information request.

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following question.

How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2024:

- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia
- Ranibizumab - Ximluci

**I have considered your request and have set out the Trust's response below:**

Description	Patient Count
Aflibercept	446
Bevacizumab - Avastin	104
Bevacizumab - Biosimilar	0
Brolucizumab	0
Dexamethasone	24
Faricimab	239
Fluocinolone acetonide	Less than 6*
Ranibizumab - Lucentis (pre-filled syringes)	0
Ranibizumab - Lucentis (vials)	0
Ranibizumab - Ongavia	612
Ranibizumab - Ximluci	0

Glen Burley, Chief Executive

Russell Hardy, Chairman

\* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,

Freedom of Information Officer

Glen Burley, Chief Executive

Russell Hardy, Chairman